Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Moorfields Eye Hospital Dubai, Dubai Healthcare City, Dubai, UAE.
Curr Opin Ophthalmol. 2023 Mar 1;34(2):176-180. doi: 10.1097/ICU.0000000000000936. Epub 2023 Jan 13.
Glaucoma drainage device (GDD) implantation surgery is commonly performed by glaucoma specialists to treat complex and refractory glaucomas. Relative safety and efficacy data from randomized controlled trials conducted in the last two decades have sparked the interest in GDDs as possible surgical options earlier in the course of the disease than has traditionally been practiced. However, until recently, advances in the design and techniques of GDD surgery have fallen short of this increasing interest.
Most recently, new GDDs that possess novel design features have become available to glaucoma specialists. Two of these new devices are the Ahmed ClearPath and the Paul glaucoma implant. These devices have demonstrated promising outcomes that are comparable to those of traditional implants. Additionally, given their unique respective features, these devices may streamline surgical technique due to ease of insertion and afford better safety and efficacy outcomes in certain patients.
The recent introduction of new GDDs has been long awaited by glaucoma surgeons. Although early results are promising, long-term data and comparison of outcomes to those of traditional filtering surgery and commonly implanted devices are needed before these devices can be the new standard of care in glaucoma tube shunt surgery.
青光眼引流装置（GDD）植入术通常由青光眼专家进行，以治疗复杂和难治性青光眼。过去二十年进行的随机对照试验提供的相对安全性和疗效数据，引发了人们对 GDD 作为疾病早期可能的手术选择的兴趣，这与传统做法不同。然而，直到最近，GDD 手术的设计和技术进展还没有跟上这种日益增长的兴趣。
最近，青光眼专家可获得具有新颖设计特点的新型 GDD。这两种新设备是 Ahmed ClearPath 和 Paul 青光眼植入物。这些设备的结果很有前景，与传统植入物的结果相当。此外，鉴于它们各自独特的特点，这些设备可能由于插入更容易而简化手术技术，并为某些患者提供更好的安全性和疗效结果。
新型 GDD 的推出是青光眼外科医生期待已久的。尽管早期结果很有希望，但需要长期数据和与传统滤过性手术以及常用植入物的结果进行比较，这些设备才能成为青光眼引流管手术的新标准。
